Oxford BioTherapeutics, an Abingdon, Oxon, UK- and San Jose, CA-based clinical-stage biotechnology company focused on developing antibody-based therapies to treat cancer, received $10m senior secured term loan.
Oxford Finance, a specialty finance firm that provides senior debt to life sciences and healthcare services companies, provided the fdinancing.
The company intends to use the funds to progress its pipeline of novel immuno-oncology and antibody drug conjugate (ADC) programs.
Led by CEO Christian Rohlff, PhD, Oxford BioTherapeutics combines immuno-oncology, Antibody-Drug Conjugate and human monoclonal antibody approaches against novel human tumor cell membrane, derived checkpoint targets identified using its target selection and validation platform, to gather compelling in vivo evidence of the effectiveness of its pipeline.
Oxford BioTherapeutics’ pipeline includes 16 product candidates, including 2 clinical and pre-clinical stage programs partnered with Menarini, 8 unpartnered ADC programs, 5 immuno-oncology programs and 2 pre-clinical stage programs partnered with Boehringer Ingelheim.
The candidates are:
– MEN1112 (OBT357), a cell-mediated cytotoxicity antibody in a phase I trial in Acute Myeloid Leukemia (AML) patients,
– MEN1309 (OBT076), an ADC for Non-Hodgkin Lymphoma (NHL), “triple negative” metastatic breast cancer and other solid cancers.